OREANDA-NEWS. JSC "Grindeks" informs that, in accordance with the Group`s budget and plan of 2013, the company is planning to invest at least 4 million lats in the development this year.

Most of the investments will be directed towards product quality assurance. The largest investment project, already underway, is the renovation of the Microbiology Laboratory and its upgrade with new technological equipment. In 2013, the planned cost of the project is 1 million lats. This year, the company plans to buy a number of product licenses and to launch the registration of these products and to implement the clinical trials. In order to increase production capacity, "Grindeks" is going to invest in acquisition and installation of certain manufacturing equipment.

Chairman of the Council of "Grindeks" Kirovs Lipmans: “Shareholders of "Grindeks", thinking about the distribution of the profit, are striving to ensure the company`s competitiveness not only from year to year, but in a long run. Since 2002, the investment amount has already reached more than 45 million lats, thus a modern pharmaceutical manufacturing company has been created that exports its products to 55 countries worldwide. Also this year, we are continuing to successfully implement the investment program and to invest in the sustainable business of the company.”

The company informs that no concrete decision has been taken regarding the establishment of new production units outside Latvia. The issue about starting a pharmacy business has not been updated up to now; in its turn, since 2012, "Grindeks" has entered into close cooperation with the individual or independent pharmacies of Latvia.